Tenax Therapeutics: How Lower Variance In Phase 3 Has "Loaded The Dice" For An Asymmetric Repricing [Seeking Alpha]
Tenax Therapeutics, Inc. (TENX)
Last tenax therapeutics, inc. earnings: 11/14 04:31 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.tenaxthera.com
Company Research
Source: Seeking Alpha
TNX-103, targeting PH-HFpEF, shows a high probability of Phase 3 success with a 65% PoS and strong Phase 2 efficacy signals. Valuation assumes $500M peak sales by 2035, conservative market penetration, and robust cash position minimizing near-term dilution risk. Market underappreciates TENX's late-stage pipeline and risk-adjusted asset value; recommend buying ahead of Phase 3 data in H2 2026. Looking for more investing ideas like this one? Get them exclusively at Vasuda Healthcare Analytics. Learn More » Design Cells/iStock via Getty Images EQUITY RESEARCH: PHARMACEUTICALS Company: Tenax Therapeutics ( TENX Investment Rating: BUY Risk Profile: Speculative/ High Risk First Price Target (12-months): Current Price Upside: Executive Summary We are initiating coverage on Tenax Therapeutics ( TENX ) with a Buy More on my IG service Premium service reviews "The best I have ever seen in the biotech space...I have been in the biotech investing space for a while
Show less
Read more
Impact Snapshot
Event Time:
TENX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TENX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TENX alerts
High impacting Tenax Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TENX
News
- Guggenheim Doubles Tenax (TENX) PT, Names Stock Top Pick [Yahoo! Finance]Yahoo! Finance
- Tenax Therapeutics (NASDAQ:TENX) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size AssessmentGlobeNewswire
- Tenax Therapeutics (NASDAQ:TENX) had its "buy" rating reaffirmed by analysts at Guggenheim.MarketBeat
- Tenax Therapeutics (NASDAQ:TENX) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
TENX
Sec Filings
- 1/9/26 - Form 8-K
- 12/23/25 - Form SCHEDULE
- 12/17/25 - Form 8-K
- TENX's page on the SEC website